Understanding how a specific protein affects immune response in bladder cancer
Official title: Novel mechanism of chemokine nitration in bladder cancer
Funded at University of Texas Hlth Science Center · NIH-11083721 · Data updated 2026-11-12
This study is looking at a protein called CCL2 and how changes to it might affect the immune system's ability to fight bladder cancer, with the hope that using a modified version of this protein could help improve treatment for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Science Center NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project start | May 3, 2024 |
| Project end | April 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $349,891 |
| NIH project number | 5R01CA281726-02 |
| Project ID | NIH-11083721 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with bladder cancer who are seeking new treatment options.
✕Less likely to help
Patients with non-cancerous bladder conditions or those who do not have bladder cancer may not benefit from this research.
What this research studies
This research investigates the role of a protein called CCL2 in bladder cancer and how its modification may impact the immune system's ability to fight the disease. The study aims to explore how CCL2, which usually helps recruit immune cells to tumors, is altered in bladder cancer, potentially hindering effective treatment. By using a modified version of CCL2 that resists this alteration, researchers hope to enhance the immune response against bladder tumors. This could lead to better treatment strategies for patients with bladder cancer.
Why it matters
Potential benefit: If successful, this research could improve the effectiveness of immunotherapy for bladder cancer patients.
How similar studies have gone: Previous research has shown promising results in enhancing immune responses through similar mechanisms, indicating potential for success in this approach.
Where this research is happening
-
University of Texas Hlth Science Center
San Antonio, United States Active
Researchers
- Principal investigator: Mukherjee, Neelam — University of Texas Hlth Science Center
- Study coordinator: Mukherjee, Neelam
Related research
Other NIH-funded projects on the same topics.
-
Population modeling to reduce bladder cancer burden
Aimed at predicting and guiding effective, population-based ways to prevent and control bladder cancer.
-
Blocking a new immune checkpoint in bladder cancer
Researchers are trying medicines that block a newly found immune pathway to help people with bladder cancer, especially those whose tumors do not respond to current immunotherapy.
-
Nrf2 in T cells and how it could boost immune power against bladder cancer
A small grant will explore how a T-cell protein called Nrf2 affects muscle-invasive bladder cancer and whether targeting it could help patients respond better to immune therapies.
-
Understanding why bladder cancer spreads and resists treatment
This grant studies how advanced bladder cancer changes and spreads across the body, aiming to uncover why it’s hard to treat.
-
Molecular clues to bladder cancer cell changes and therapy response
This NIH grant looks at how bladder cancer cells change their identity and how that affects response to treatment, with a focus on aggressive neuroendocrine variants.
-
Repurposing spironolactone to treat bladder cancer inside the bladder
Aims to repurpose spironolactone as an intravesical treatment for non-muscle invasive bladder cancer to help prevent recurrence and progression.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.